The State of Metabolic Health in America, 2026 Baseline Edition
Annual Policy Report · James M. Knox · Published 2026 · DOI: 10.5281/zenodo.22772957 · ISSN 3144-8178 (Online)
The State of Metabolic Health in America, 2026 Baseline Edition is an independently authored annual policy reference that consolidates national data on the prevalence, cost, and policy treatment of metabolic health conditions in the United States. It presents 98 metrics across ten series, and every statistic cites a primary source. Where data are missing or sources conflict, the report says so rather than estimating.
About This Report
This report covers the prevalence of metabolic health conditions among U.S. adults, the cost burden those conditions place on employers and public programs, and the policy and clinical interventions designed to address them. Its purpose is to provide a stable, citable reference that benefits professionals, policy staff, journalists, and researchers can use without having to reconcile conflicting estimates from different sources. The report is independently authored and does not represent the position of any employer, insurer, vendor, or government agency.
| Edition | 2026 Baseline |
| Pages | 245 |
| Metrics | 98 |
| Series | 10 |
| Figures | 28 |
| Next edition | 2027 |
Key Figures
Headline statistics from the report. Each links to its metric page.
40.3%
Adult obesity prevalence among U.S. adults, based on measured height and weight, 2023.
Source: CDC, NCHS, 2023
More than 115 million
U.S. adults living with prediabetes — the majority unaware of their status, 2024.
Source: CDC, National Diabetes Statistics Report, 2024
$412.9 billion
Total annual economic cost of diagnosed diabetes in the United States, 2022.
Source: American Diabetes Association, 2022
$26,993
Average annual employer-sponsored family health insurance premium per covered worker, 2024.
Source: KFF Employer Health Benefits Survey, 2024
67 million
Medicare beneficiaries enrolled in the program as of 2024.
Source: CMS, Medicare Enrollment Dashboard, 2024
79.8 million
Total Medicaid and CHIP enrollment at peak in April 2023, before the unwinding of continuous enrollment.
Source: CMS, Medicaid Enrollment Data, 2023
Key figures will be populated when the full metric dataset is provided. View all 98 metrics →
The Ten Series
National prevalence of metabolic health conditions among U.S. adults, including obesity, diabetes, prediabetes, hypertension, chronic kidney disease, and metabolic syndrome, with attention to how these conditions cluster in the same individuals.
The direct and indirect economic burden of metabolic disease in the United States, including national health expenditures, diabetes cost estimates, employer productivity losses, and mortality disparities by geography and race.
Employer-sponsored health insurance costs, worker premium contributions, self-funded plan enrollment, and employer coverage decisions for GLP-1 medications, including coverage rates and utilization requirements.
Metabolic disease burden among Medicare beneficiaries, Medicare Advantage supplemental benefit availability, the Medicare Diabetes Prevention Program, and the CMS ACCESS model for cardio-kidney-metabolic conditions.
Medicaid and CHIP enrollment trends, cardiometabolic disease burden among Medicaid adults, state GLP-1 coverage decisions, and Section 1115 waiver activity addressing health-related social needs.
State-level obesity and diabetes prevalence, regional variation, rural-urban disparities, and the public health infrastructure available to address metabolic conditions across U.S. communities.
State and regional variation in hypertension, diabetes, and obesity prevalence, including self-reported versus measured differences, rural-urban gaps within states, and racial and ethnic variation across geographies.
Medicaid innovation programs addressing metabolic health, including Section 1115 waiver pilots, the North Carolina Healthy Opportunities Pilots, and state-level GLP-1 coverage changes and their documented outcomes.
Medicare innovation models targeting metabolic and cardio-kidney-metabolic conditions, including the CMS ACCESS model design, payment mechanics, biomarker requirements, and the Medicare Diabetes Prevention Program scale gap.
Employer benefit design decisions for GLP-1 medications, including coverage continuation intent, utilization control tightening, and variation across employer surveys with different populations and question designs.
Data Gaps
This report names what national data do not measure, rather than estimating around the gaps. Where a metric cannot be reported because no adequate national data source exists, the report records the gap explicitly. View the full data gaps list →
How This Report Was Built
Each metric was drawn from a named primary source — a federal survey, peer-reviewed study, or government administrative dataset — with the source, data year, and population stated alongside the figure. Where two sources reported different values for the same metric, both figures and the reason for the difference are stated rather than choosing between them. The report does not model, project, or extrapolate from available data. Full methodology →
Read or Download the Full Report
How to Cite
About the Author
James M. Knox is a writer and researcher focused on metabolic health, employee benefits, and health policy. He is the editorial director of Grapefruit Life and the author of The Health Dividend (forthcoming, 2027). Full biography and research profiles →
Updates
No updates recorded since publication. View full update log →